What is China Sxt Pharmaceuticals Inc's earnings per share (EPS)?

China Sxt Pharmaceuticals Inc (SXTC) reported diluted earnings per share of $-2.32 for fiscal year 2025. This represents a 91.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

China Sxt Pharmaceuticals Inc Financials

SXTC

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2025 Currency USD FYE March

This page shows China Sxt Pharmaceuticals Inc (SXTC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 37/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

China Sxt Pharmaceuticals Inc has an operating margin of -154.0%, meaning the company retains $-154 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -130.4% the prior year.

Growth

China Sxt Pharmaceuticals Inc's revenue declined 9.7% year-over-year, from $1.9M to $1.7M. This contraction results in a growth score of 17/100.

Leverage

100

China Sxt Pharmaceuticals Inc carries a low D/E ratio of 0.01, meaning only $0.01 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.54, China Sxt Pharmaceuticals Inc holds $3.54 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 69/100.

Returns

China Sxt Pharmaceuticals Inc generates a -21.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -22.2% the prior year.

Piotroski F-Score Weak

3/9

China Sxt Pharmaceuticals Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.71x

For every $1 of reported earnings, China Sxt Pharmaceuticals Inc generates $0.71 in operating cash flow (-$2.3M OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-25.2x

China Sxt Pharmaceuticals Inc earns $-25.2 in operating income for every $1 of interest expense (-$2.7M vs $106K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.7M

YoY-9.7%

5Y CAGR-19.5%

China Sxt Pharmaceuticals Inc generated $1.7M in revenue in fiscal year 2025. This represents a decrease of 9.7% from the prior year.

EBITDA

-$2.6M

YoY-12.4%

China Sxt Pharmaceuticals Inc's EBITDA was -$2.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.4% from the prior year.

Net Income

-$3.3M

YoY-6.6%

China Sxt Pharmaceuticals Inc reported -$3.3M in net income in fiscal year 2025. This represents a decrease of 6.6% from the prior year.

EPS (Diluted)

$-2.32

YoY+91.9%

China Sxt Pharmaceuticals Inc earned $-2.32 per diluted share (EPS) in fiscal year 2025. This represents an increase of 91.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$18.1M

YoY+49.9%

5Y CAGR+20.0%

China Sxt Pharmaceuticals Inc held $18.1M in cash against $96K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

China Sxt Pharmaceuticals Inc had 0 shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

21.1%

YoY-7.6pp

5Y CAGR-31.3pp

China Sxt Pharmaceuticals Inc's gross margin was 21.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 7.6 percentage points from the prior year.

Operating Margin

-154.0%

YoY-23.6pp

5Y CAGR-128.0pp

China Sxt Pharmaceuticals Inc's operating margin was -154.0% in fiscal year 2025, reflecting core business profitability. This is down 23.6 percentage points from the prior year.

Net Margin

-189.8%

YoY-29.1pp

5Y CAGR+9.5pp

China Sxt Pharmaceuticals Inc's net profit margin was -189.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 29.1 percentage points from the prior year.

Return on Equity

-21.4%

YoY+0.8pp

5Y CAGR+88.0pp

China Sxt Pharmaceuticals Inc's ROE was -21.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 0.8 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

SXTC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.7M-9.7%	$1.9M-2.2%	$2.0M-24.2%	$2.6M-45.5%	$4.8M-7.5%	$5.2M
Cost of Revenue	$1.4M-0.1%	$1.4M-11.1%	$1.5M+14.4%	$1.4M-30.3%	$1.9M-21.2%	$2.5M
Gross Profit	$367K-33.7%	$554K+30.0%	$426K-65.9%	$1.3M-55.9%	$2.8M+5.0%	$2.7M
R&D Expenses	N/A	$184K-8.2%	$201K-45.3%	$367K	N/A	N/A
SG&A Expenses	$2.8M+4.6%	$2.6M-53.3%	$5.6M+2.3%	$5.5M+59.9%	$3.4M+40.1%	$2.5M
Operating Income	-$2.7M-6.6%	-$2.5M+55.1%	-$5.6M-8.1%	-$5.2M-136.2%	-$2.2M-63.8%	-$1.3M
Interest Expense	$106K-54.1%	$232K-51.4%	$477K+1199.3%	$37K-97.7%	$1.6M-51.8%	$3.3M
Income Tax	N/A	N/A	N/A	$328K+270.3%	-$193K-89.4%	-$102K
Net Income	-$3.3M-6.6%	-$3.1M+47.8%	-$5.9M-3.5%	-$5.7M-108.7%	-$2.7M+73.3%	-$10.3M
EPS (Diluted)	$-2.32+91.9%	$-28.58+83.9%	$-177.84	$-137.92-3511.4%	$-3.82	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SXTC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$21.7M-6.3%	$23.1M-21.7%	$29.6M-11.9%	$33.5M-2.9%	$34.5M+59.2%	$21.7M
Current Assets	$21.3M+49.6%	$14.2M-27.1%	$19.5M-13.1%	$22.5M-3.4%	$23.2M+18.3%	$19.6M
Cash & Equivalents	$18.1M+49.9%	$12.1M-30.5%	$17.4M+11.9%	$15.5M+16.4%	$13.3M+83.0%	$7.3M
Inventory	$828K+4.2%	$795K+49.6%	$531K-47.8%	$1.0M+18.4%	$860K-3.7%	$893K
Accounts Receivable	$1.3M-1.0%	$1.3M-2.2%	$1.3M-59.7%	$3.3M-26.0%	$4.5M+18.0%	$3.8M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.2M-32.3%	$9.2M-38.1%	$14.9M-13.2%	$17.1M-7.9%	$18.6M+51.1%	$12.3M
Current Liabilities	$6.0M-32.5%	$8.9M-38.6%	$14.5M-15.3%	$17.1M-7.8%	$18.6M+51.5%	$12.3M
Long-Term Debt	$96K-17.8%	$117K-0.6%	$118K	N/A	$6K-82.8%	$37K
Total Equity	$15.4M+10.8%	$13.9M-5.2%	$14.7M-8.7%	$16.1M+0.8%	$16.0M+69.8%	$9.4M
Retained Earnings	-$28.0M-13.4%	-$24.7M-14.3%	-$21.6M-37.8%	-$15.7M-57.6%	-$10.0M-38.1%	-$7.2M

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Total Assets	$21.7M-30.1%	$31.0M+34.0%	$23.1M+58.5%	$14.6M-50.6%	$29.6M+33.2%	$22.2M-33.9%	$33.5M+48.0%	$22.7M
Current Assets	$21.3M-3.1%	$22.0M+54.5%	$14.2M+5.5%	$13.5M-30.9%	$19.5M+57.9%	$12.4M-44.9%	$22.5M+92.5%	$11.7M
Cash & Equivalents	$18.1M-2.2%	$18.5M+53.4%	$12.1M+5.3%	$11.5M-34.0%	$17.4M+482.6%	$3.0M-80.8%	$15.5M+49465.2%	$31K
Inventory	$828K-4.5%	$867K+9.1%	$795K+61.2%	$493K-7.2%	$531K-15.4%	$628K-38.3%	$1.0M+21.5%	$837K
Accounts Receivable	$1.3M-21.8%	$1.7M+26.6%	$1.3M+0.3%	$1.3M-2.5%	$1.3M-59.5%	$3.3M-0.3%	$3.3M-14.2%	$3.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.2M-61.0%	$16.0M+73.6%	$9.2M-3.3%	$9.5M-36.0%	$14.9M+103.8%	$7.3M-57.4%	$17.1M+92.8%	$8.9M
Current Liabilities	$6.0M-61.6%	$15.7M+76.0%	$8.9M-3.2%	$9.2M-36.5%	$14.5M+98.8%	$7.3M-57.4%	$17.1M+92.8%	$8.9M
Long-Term Debt	$96K-16.5%	$115K-1.5%	$117K+9.9%	$107K-9.6%	$118K	N/A	N/A	N/A
Total Equity	$15.4M+2.7%	$15.0M+7.9%	$13.9M+174.4%	$5.1M-65.4%	$14.7M+1.0%	$14.5M-9.5%	$16.1M+16.6%	$13.8M
Retained Earnings	-$28.0M-9.8%	-$25.5M-3.2%	-$24.7M+21.1%	-$31.3M-44.9%	-$21.6M-25.8%	-$17.2M-9.5%	-$15.7M-20.3%	-$13.0M

SXTC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$2.3M-21.6%	-$1.9M-2287.5%	-$81K-130.1%	$268K+120.4%	-$1.3M-240.9%	$934K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$131K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	$803K
Investing Cash Flow	$64K+140.4%	$26K+314.8%	-$12K+73.8%	-$47K+99.2%	-$5.8M-5.6%	-$5.5M
Financing Cash Flow	$8.4M+420.0%	-$2.6M-189.2%	$2.9M+84.4%	$1.6M-87.1%	$12.4M+310.3%	$3.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SXTC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	21.1%-7.6pp	28.7%+7.1pp	21.6%-26.5pp	48.1%-11.3pp	59.4%+7.1pp	52.4%
Operating Margin	-154.0%-23.6pp	-130.4%+154.0pp	-284.4%-85.0pp	-199.4%-153.4pp	-46.0%-20.0pp	-26.0%
Net Margin	-189.8%-29.1pp	-160.7%+140.3pp	-301.0%-80.6pp	-220.4%-162.9pp	-57.5%+141.8pp	-199.3%
Return on Equity	-21.4%+0.8pp	-22.2%+18.2pp	-40.4%-4.7pp	-35.7%-18.5pp	-17.2%+92.2pp	-109.4%
Return on Assets	-15.3%-1.8pp	-13.4%+6.7pp	-20.1%-3.0pp	-17.1%-9.2pp	-8.0%+39.4pp	-47.4%
Current Ratio	3.54+1.9	1.60+0.3	1.35+0.0	1.31+0.1	1.25-0.4	1.60
Debt-to-Equity	0.010.0	0.010.0	0.01-1.1	1.06+1.1	0.000.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	15.6%

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	3.54+2.1	1.40-0.2	1.60+0.1	1.47+0.1	1.35-0.3	1.70+0.4	1.310.0	1.31
Debt-to-Equity	0.010.0	0.010.0	0.01-0.0	0.02+0.0	0.01-0.5	0.50-0.6	1.06+0.4	0.64
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Ironwood IRWD

$577.2M

Journey Medical Corp DERM

$135.3M

Organigram Global Inc OGI

$188.1M

Alpha Teknova TKNO

$169.3M

BioAge Labs Inc. BIOA

$776.6M

Frequently Asked Questions

What is China Sxt Pharmaceuticals Inc's annual revenue?

China Sxt Pharmaceuticals Inc (SXTC) reported $1.7M in total revenue for fiscal year 2025. This represents a -9.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is China Sxt Pharmaceuticals Inc's revenue growing?

China Sxt Pharmaceuticals Inc (SXTC) revenue declined by 9.7% year-over-year, from $1.9M to $1.7M in fiscal year 2025.

Is China Sxt Pharmaceuticals Inc profitable?

No, China Sxt Pharmaceuticals Inc (SXTC) reported a net income of -$3.3M in fiscal year 2025, with a net profit margin of -189.8%.

What is China Sxt Pharmaceuticals Inc's EBITDA?

China Sxt Pharmaceuticals Inc (SXTC) had EBITDA of -$2.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does China Sxt Pharmaceuticals Inc have?

As of fiscal year 2025, China Sxt Pharmaceuticals Inc (SXTC) had $18.1M in cash and equivalents against $96K in long-term debt.

What is China Sxt Pharmaceuticals Inc's gross margin?

China Sxt Pharmaceuticals Inc (SXTC) had a gross margin of 21.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is China Sxt Pharmaceuticals Inc's operating margin?

China Sxt Pharmaceuticals Inc (SXTC) had an operating margin of -154.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is China Sxt Pharmaceuticals Inc's net profit margin?

China Sxt Pharmaceuticals Inc (SXTC) had a net profit margin of -189.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is China Sxt Pharmaceuticals Inc's return on equity (ROE)?

China Sxt Pharmaceuticals Inc (SXTC) has a return on equity of -21.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is China Sxt Pharmaceuticals Inc's operating cash flow?

China Sxt Pharmaceuticals Inc (SXTC) generated -$2.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are China Sxt Pharmaceuticals Inc's total assets?

China Sxt Pharmaceuticals Inc (SXTC) had $21.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does China Sxt Pharmaceuticals Inc have outstanding?

China Sxt Pharmaceuticals Inc (SXTC) had 0 shares outstanding as of fiscal year 2025.

What is China Sxt Pharmaceuticals Inc's current ratio?

China Sxt Pharmaceuticals Inc (SXTC) had a current ratio of 3.54 as of fiscal year 2025, which is generally considered healthy.

What is China Sxt Pharmaceuticals Inc's debt-to-equity ratio?

China Sxt Pharmaceuticals Inc (SXTC) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is China Sxt Pharmaceuticals Inc's return on assets (ROA)?

China Sxt Pharmaceuticals Inc (SXTC) had a return on assets of -15.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is China Sxt Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, China Sxt Pharmaceuticals Inc (SXTC) had $18.1M in cash against an annual operating cash burn of $2.3M. This gives an estimated cash runway of approximately 93 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is China Sxt Pharmaceuticals Inc's Piotroski F-Score?

China Sxt Pharmaceuticals Inc (SXTC) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are China Sxt Pharmaceuticals Inc's earnings high quality?

China Sxt Pharmaceuticals Inc (SXTC) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can China Sxt Pharmaceuticals Inc cover its interest payments?

China Sxt Pharmaceuticals Inc (SXTC) has an interest coverage ratio of -25.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is China Sxt Pharmaceuticals Inc?

China Sxt Pharmaceuticals Inc (SXTC) scores 37 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.